Evaluation of trimethoprim-sulfamethoxazole based combination therapy against Stenotrophomonas maltophilia: in vitro effects and clinical efficacy in cancer patients

Objectives: The aim of this study was to evaluate the in vitro effects and clinical efficacies of trimethoprim-sulfamethoxazole (SXT) combined with other antimicrobial agents against Stenotrophomonas maltophilia. Methods: In vitro analysis was conducted on 89 S. maltophilia strains isolated from blo...

Full description

Bibliographic Details
Main Authors: Hideki Araoka, Masaru Baba, Chikako Okada, Masahiro Abe, Muneyoshi Kimura, Akiko Yoneyama
Format: Article
Language:English
Published: Elsevier 2017-05-01
Series:International Journal of Infectious Diseases
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971217300681
_version_ 1818606538856595456
author Hideki Araoka
Masaru Baba
Chikako Okada
Masahiro Abe
Muneyoshi Kimura
Akiko Yoneyama
author_facet Hideki Araoka
Masaru Baba
Chikako Okada
Masahiro Abe
Muneyoshi Kimura
Akiko Yoneyama
author_sort Hideki Araoka
collection DOAJ
description Objectives: The aim of this study was to evaluate the in vitro effects and clinical efficacies of trimethoprim-sulfamethoxazole (SXT) combined with other antimicrobial agents against Stenotrophomonas maltophilia. Methods: In vitro analysis was conducted on 89 S. maltophilia strains isolated from blood and the respiratory tract between June 2012 and October 2014. Levofloxacin (LVX), ticarcillin-clavulanic acid (TIM), and minocycline (MIN) were selected for an examination of their effects when individually combined with SXT by the checkerboard method. In addition, 29 S. maltophilia bacteremia cases were reviewed and the clinical efficacies of SXT-based combination therapies were analyzed. Results: SXT + LVX showed synergy in 21, no interactions in 61, and antagonism in 7. SXT + TIM showed synergy in 71, and no interactions in 18. SXT + MIN showed synergy in 10, and no interactions in 79. The review of clinical data indicated that a combination of SXT + fluoroquinolone was not associated with improved prognosis compared with monotherapy. Conclusions: The in vitro data indicated that SXT + TIM had beneficial microbiological effects and was not antagonistic. Our in vitro and clinical data analyses do not support the routine use of SXT + fluoroquinolone combination therapy for S. maltophilia infection.
first_indexed 2024-12-16T14:12:27Z
format Article
id doaj.art-51fb53521a774fcaa34f34733c4ad6a2
institution Directory Open Access Journal
issn 1201-9712
1878-3511
language English
last_indexed 2024-12-16T14:12:27Z
publishDate 2017-05-01
publisher Elsevier
record_format Article
series International Journal of Infectious Diseases
spelling doaj.art-51fb53521a774fcaa34f34733c4ad6a22022-12-21T22:28:43ZengElsevierInternational Journal of Infectious Diseases1201-97121878-35112017-05-0158C182110.1016/j.ijid.2017.02.020Evaluation of trimethoprim-sulfamethoxazole based combination therapy against Stenotrophomonas maltophilia: in vitro effects and clinical efficacy in cancer patientsHideki Araoka0Masaru Baba1Chikako Okada2Masahiro Abe3Muneyoshi Kimura4Akiko Yoneyama5Department of Infectious Diseases, Toranomon Hospital, Tokyo, JapanDepartment of Infectious Diseases, Toranomon Hospital, Tokyo, JapanDepartment of Infectious Diseases, Toranomon Hospital, Tokyo, JapanDepartment of Infectious Diseases, Toranomon Hospital, Tokyo, JapanDepartment of Infectious Diseases, Toranomon Hospital, Tokyo, JapanDepartment of Infectious Diseases, Toranomon Hospital, Tokyo, JapanObjectives: The aim of this study was to evaluate the in vitro effects and clinical efficacies of trimethoprim-sulfamethoxazole (SXT) combined with other antimicrobial agents against Stenotrophomonas maltophilia. Methods: In vitro analysis was conducted on 89 S. maltophilia strains isolated from blood and the respiratory tract between June 2012 and October 2014. Levofloxacin (LVX), ticarcillin-clavulanic acid (TIM), and minocycline (MIN) were selected for an examination of their effects when individually combined with SXT by the checkerboard method. In addition, 29 S. maltophilia bacteremia cases were reviewed and the clinical efficacies of SXT-based combination therapies were analyzed. Results: SXT + LVX showed synergy in 21, no interactions in 61, and antagonism in 7. SXT + TIM showed synergy in 71, and no interactions in 18. SXT + MIN showed synergy in 10, and no interactions in 79. The review of clinical data indicated that a combination of SXT + fluoroquinolone was not associated with improved prognosis compared with monotherapy. Conclusions: The in vitro data indicated that SXT + TIM had beneficial microbiological effects and was not antagonistic. Our in vitro and clinical data analyses do not support the routine use of SXT + fluoroquinolone combination therapy for S. maltophilia infection.http://www.sciencedirect.com/science/article/pii/S1201971217300681Stenotrophomonas maltophiliacombination therapytrimethoprim-sulfamethoxazolefluoroquinolonesticarcillin-clavulanic acidcancer patients
spellingShingle Hideki Araoka
Masaru Baba
Chikako Okada
Masahiro Abe
Muneyoshi Kimura
Akiko Yoneyama
Evaluation of trimethoprim-sulfamethoxazole based combination therapy against Stenotrophomonas maltophilia: in vitro effects and clinical efficacy in cancer patients
International Journal of Infectious Diseases
Stenotrophomonas maltophilia
combination therapy
trimethoprim-sulfamethoxazole
fluoroquinolones
ticarcillin-clavulanic acid
cancer patients
title Evaluation of trimethoprim-sulfamethoxazole based combination therapy against Stenotrophomonas maltophilia: in vitro effects and clinical efficacy in cancer patients
title_full Evaluation of trimethoprim-sulfamethoxazole based combination therapy against Stenotrophomonas maltophilia: in vitro effects and clinical efficacy in cancer patients
title_fullStr Evaluation of trimethoprim-sulfamethoxazole based combination therapy against Stenotrophomonas maltophilia: in vitro effects and clinical efficacy in cancer patients
title_full_unstemmed Evaluation of trimethoprim-sulfamethoxazole based combination therapy against Stenotrophomonas maltophilia: in vitro effects and clinical efficacy in cancer patients
title_short Evaluation of trimethoprim-sulfamethoxazole based combination therapy against Stenotrophomonas maltophilia: in vitro effects and clinical efficacy in cancer patients
title_sort evaluation of trimethoprim sulfamethoxazole based combination therapy against stenotrophomonas maltophilia in vitro effects and clinical efficacy in cancer patients
topic Stenotrophomonas maltophilia
combination therapy
trimethoprim-sulfamethoxazole
fluoroquinolones
ticarcillin-clavulanic acid
cancer patients
url http://www.sciencedirect.com/science/article/pii/S1201971217300681
work_keys_str_mv AT hidekiaraoka evaluationoftrimethoprimsulfamethoxazolebasedcombinationtherapyagainststenotrophomonasmaltophiliainvitroeffectsandclinicalefficacyincancerpatients
AT masarubaba evaluationoftrimethoprimsulfamethoxazolebasedcombinationtherapyagainststenotrophomonasmaltophiliainvitroeffectsandclinicalefficacyincancerpatients
AT chikakookada evaluationoftrimethoprimsulfamethoxazolebasedcombinationtherapyagainststenotrophomonasmaltophiliainvitroeffectsandclinicalefficacyincancerpatients
AT masahiroabe evaluationoftrimethoprimsulfamethoxazolebasedcombinationtherapyagainststenotrophomonasmaltophiliainvitroeffectsandclinicalefficacyincancerpatients
AT muneyoshikimura evaluationoftrimethoprimsulfamethoxazolebasedcombinationtherapyagainststenotrophomonasmaltophiliainvitroeffectsandclinicalefficacyincancerpatients
AT akikoyoneyama evaluationoftrimethoprimsulfamethoxazolebasedcombinationtherapyagainststenotrophomonasmaltophiliainvitroeffectsandclinicalefficacyincancerpatients